Zobrazeno 1 - 4
of 4
pro vyhledávání: '"E P H, Colbers"'
Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects
Autor:
E, Spaans, M W, van den Heuvel, P G, Schnabel, P A M, Peeters, U G, Chin-Kon-Sung, E P H, Colbers, J M A, Sitsen
Publikováno v:
European Journal of Clinical Pharmacology. 58:423-429
The objectives of this study were to assess the effect of mirtazapine on steady-state pharmacokinetics of phenytoin and vice versa and to assess tolerability and safety of the combined use of mirtazapine and phenytoin.This was an open-label, randomis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc9f5c84da6a288ea184108fc6470c24
https://doi.org/10.1007/s00228-002-0498-6
https://doi.org/10.1007/s00228-002-0498-6
Autor:
A, Jansen, E P H, Colbers, A J A M, van der Ven, C, Richter, J K, Rockstroh, J C, Wasmuth, M, van Luin, D M, Burger
Publikováno v:
HIV medicine. 14(7)
To evaluate the use of raltegravir with unboosted atazanavir in combination with one nucleoside reverse transcriptase inhibitor (NRTI) (lamivudine or emtricitabine) as a potentially well-tolerated once-daily (qd) maintenance regimen.We compared the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2498cdcfa39a61c0d5da0593a91896b7
https://pubmed.ncbi.nlm.nih.gov/23506243
https://pubmed.ncbi.nlm.nih.gov/23506243
Autor:
Yechiel A. Hekster, David M. Burger, C.J.L. la Porte, E. P. H. Colbers, M. J. A. De Graaff-Teulen, S. Marco Ibanez, Peter P. Koopmans, D. S. Voncken
Publikováno v:
British Journal of Clinical Pharmacology, 58, 6, pp. 632-40
British Journal of Clinical Pharmacology, 58, 632-40
British Journal of Clinical Pharmacology, 58, 632-40
Contains fulltext : 57225.pdf (Publisher’s version ) (Closed access) AIMS: A once-daily (q.d.) nucleoside-sparing regimen can prevent mitochondrial toxicity, overcome viral resistance and improve compliance. In the present study the effect of efavi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::855482155aa2bd5311a17d5bbe3555a0
https://doi.org/10.1111/j.1365-2125.2004.02214.x
https://doi.org/10.1111/j.1365-2125.2004.02214.x
Autor:
Yechiel A. Hekster, E. P. H. Colbers, David M. Burger, R.J. Bertz, D. S. Voncken, K. Wikstrom, Martin J. Boeree, C.J.L. la Porte, Peter P. Koopmans
Publikováno v:
Antimicrobial Agents and Chemotherapy, 48, 1553-60
Antimicrobial Agents and Chemotherapy, 48, 5, pp. 1553-60
Antimicrobial Agents and Chemotherapy, 48, 5, pp. 1553-60
Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous agent rifampin is contraindicated because of a significant pharmacokinetic interaction due to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::622ff3e3e8eec9a41d357e864ec21152
https://doi.org/10.1128/AAC.48.5.1553-1560.2004
https://doi.org/10.1128/AAC.48.5.1553-1560.2004